関連ニュース

Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-re

Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expan

Portfolios are commonly underexposed to the companies driving healthcare innovation. As technological disruptions build across medical fields, the ROBO Global Healthcare Technology and Innovation ETF